Literature for ABT-450 (S29.001 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2019
1. Jensen,S.B., Fahnoe,U., Pham,L.V., Serre,S.B.N., Tang,Q., Ghanem,L., Pedersen,M.S., Ramirez,S., Humes,D., Pihl,A.F., Filskov,J., Solund,C.S., Dietz,J., Fourati,S., Pawlotsky,J.M., Sarrazin,C., Weis,N., Schonning,K., Krarup,H., Bukh,J. and Gottwein,J.M.
   Evolutionary pathways to persistence of highly fit and resistant hepatitis C virus protease inhibitor escape variants
   Hepatology70, 771-787. PubMed  Europe PubMed DOI  I
2014
2. Gentile,I., Borgia,F., Buonomo,A.R., Zappulo,E., Castaldo,G. and Borgia,G.
   ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection
   Curr Med Chem21, 3261-3270. PubMed  Europe PubMed DOI  I
3. Poordad,F., Hezode,C., Trinh,R., Kowdley,K.V., Zeuzem,S., Agarwal,K., Shiffman,M.L., Wedemeyer,H., Berg,T., Yoshida,E.M., Forns,X., Lovell,S.S., Da Silva-Tillmann,B., Collins,C.A., Campbell,A.L., Podsadecki,T. and Bernstein,B.
   ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
   N Engl J Med370, 1973-1982. PubMed  Europe PubMed DOI  I